Avendus Capital Ventures

Avendus is one of India’s top-tier investment banks and asset managers with a venture-and-growth investing arm, writing Series B, Series C, and growth-stage checks in the $5M to $25M range. The platform’s healthcare credibility is anchored by both its banking practice, which has advised landmark Indian healthcare transactions, and its investing activity, which includes employee health benefits platform Plum, which Avendus advised on its INR 193 crore Series B led by Peak XV with participation from Tanglin and GMO. The right counterparty for Avendus’s investing arm is a CEO of an Indian healthcare or wellness company at meaningful revenue scale, with cohort discipline, audited financials, and a credible exit pathway through IPO, strategic, or secondary. Healthcare relevance includes digital health platforms, employee health and benefits, wellness consumer brands with proven economics, and tech-enabled care delivery. Founders pursuing biotech assets, early-stage AI, or pure software at Seed should look at specialist or earlier-stage capital. Geographic and structural advantage is the Avendus banking franchise. Few Indian growth investors have the same depth of relationships with Indian healthcare strategics, public markets desks, and global PE firms, which compounds during exit planning. The flip side is institutional cadence: diligence is rigorous, post-investment information rights are deep, and decision cycles reflect a regulated bank-and-asset-manager structure. Best entry is via established Indian banker relationships, Tier-1 Indian VC syndicates that have co-invested with Avendus, or direct outreach when revenue is at the level the firm takes seriously. The healthcare investing team is small and selective, so cold inbound conversion is low. Lead the pitch with audited financials, cohort and operational metrics, regulator and clinical quality systems where relevant, and a credible exit pathway. Be explicit about any related-party transactions, governance history, and material litigation, because these surface during diligence. Caveats: Avendus is a complex multi-business platform, so founders should clarify which entity within the group is investing, what the fund or vehicle structure is, and how alignment with the broader bank is managed across advisory and investing activities. Ask directly about LP base, governance preferences, and how follow-on is handled in down cycles. Reference checks with portfolio CEOs on board behavior, banking-investing alignment, and value beyond capital are essential. Used appropriately, Avendus is one of the more credible India growth partners for healthcare CEOs at scale; for founders earlier in the journey, it is structurally premature.